Cost-savings of adalimumab in hidradenitis suppurativa: A retrospective analysis of a real-world cohort.

CONCLUSIONS: Treatment with anti-TNFs achieves significant cost-benefit through containment of HS exacerbations. The efficacy of anti-TNFs was similar for both disease stages. This article is protected by copyright. All rights reserved.
PMID: 30192377 [PubMed - as supplied by publisher]

Source: The British Journal of Dermatology - September 7, 2018 Category: Dermatology Authors: Argyropoulou M, Kanni T, Kyprianou M, Melachroinopoulos N, Giamarellos-Bourboulis EJ Tags: Br J Dermatol Source Type: research